RET重排与甲状腺乳头状癌关系的研究进展  

Research Progress on the Relationship Between RET Rearrangement and Papillary Thyroid Carcinoma

作　　者：钱秋琴 刘英 文鹏 石峰 QIAN Qiuqin;LIU Ying;WEN Peng;SHI Feng(Department of Thyroid Medicine/Nuclide Treatment Ward,the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University/Hunan Cancer Hospital,Changsha,Hunan,410013,China)

机构地区：[1]中南大学湘雅医学院附属肿瘤医院/湖南省肿瘤医院甲状腺内科/核素治疗病房,湖南长沙410013

出　　处：《肿瘤药学》2021年第3期289-292,299,共5页Anti-Tumor Pharmacy

基　　金：湖南省自然科学基金项目(2018JJ6026)。

摘　　要：RET原癌基因是甲状腺乳头状癌(PTC)的特异性基因。多项研究显示,RET重排在PTC中的发生率约2.5%~73%,并与PTC侵袭性行为、远处转移等不良预后密切相关。2020年,单靶点RET基因抑制剂Selpercatinib获批上市,用于治疗RET重排阳性肿瘤患者,为RET/PTC患者带来了希望。本文主要对RET重排的致病机制及其在PTC术前诊断、预后判断及治疗中的作用进行综述,希望此靶基因能够成为PTC治疗的新突破口。The RET proto-oncogene is a specific gene for papillary thyroid carcinoma(PTC).A number of studies have shown that the incidence of RET rearrangement in PTC is about 2.5%~73%,and it is closely related to poor prognosis such as PTC aggressive behavior and distant metastasis.In 2020,the single-target RET gene inhibitor,selpercatinib,was approved for the first time on the market,to treat tumor patients with RET rearrangement.This undoubtedly brings hope to RET/PTC patients.Thereby,we mainly reviewed in this paper the pathogenesis of RET gene rearrangement and its roles in preoperative diagnosis,prognosis and treatment of PTC.It is expected that this target gene could become a new breakthrough in the treatment of PTC.

关 键 词：甲状腺乳头状癌 RET原癌基因 RET/PTC重排 

分 类 号：R736.1[医药卫生—肿瘤]